摘要
目的:通过对食管癌患者血清结合珠蛋白水平的检测,探讨其在食管癌诊断及疗效评估中的意义。方法:用酶联免疫吸附法(ELISA)测定40名健康志愿者、60例食管癌患者血清结合珠蛋白的浓度。结果:治疗前食管癌组血清结合珠蛋白浓度明显高于正常组(P<0.01),Ⅲ-Ⅳ期食管癌患者血清结合珠蛋白浓度明显高于Ⅰ-Ⅱ期组(均P<0.01)。经全身化疗的患者血清结合珠蛋白在部分缓解组浓度明显低于治疗前(P<0.01),而稳定组及进展组治疗前后浓度差异无统计学意义。结论:血清结合珠蛋白浓度在食管癌患者中明显升高,且与临床分期相关,是一个较好的食管癌诊断和临床分期的辅助指标,并且有助于临床对食管癌疗效的评估。
Objective:To study the clinic significance of serum haptoglobin levels in esophageal carcinoma patients.Methods:Forty healthy volunteers and sixty patients with esophageal cancer were detected the serum haptoglobin levels by ELASA.Results:The serum haptoglobin levels in esophageal carcinoma patients were significantly higher than controls(P<0.01).The levels of serum haptoglobin were significantly higher in patients withⅢ-Ⅳstage than in patients withⅠ-Ⅱstage(P<0.01).Furthermore,the serum haptoglobin levels in esophageal carcinoma patients of therapeutic evaluation PR were decreased significantly after chemotherapy(P<0.01).Conclusion:Detection of serum haptoglobin might be helpful for diagnosis,efficacy evaluation and disease monitoring for esophageal carcinoma patients.
作者
林勇龙
赖奕静
廖泽飞
马良赟
LIN Yonglong;LAI Yijing;LIAO Zefei;MA Liangyun(Department of Thoracic Surgery,910 Hospital of Joint Logistics Support Force,Fujian Quanzhou 362000,China)
出处
《现代肿瘤医学》
CAS
北大核心
2021年第1期49-51,共3页
Journal of Modern Oncology
基金
泉州市科技计划项目(编号:2018N140S)。
关键词
结合珠蛋白
食管癌
分期
疗效
haptoglobin
esophageal cancer
stage
curative effect
